The Sunday Feb 17 issue of Biospectrum Asia http://www.biospectrumasia.com/content/150208CHN5535.asp
had the following announcement.
"SurExam commercializes ovarian cancer detection technology in China
Singapore, Feb 15, 2008: The Yale University Office of Cooperative Research has granted an exclusive license to Chinese biopharmaceutical company SurExam Life Science & Technology for the commercialization of the university's blood testing technology for epithelial ovarian cancer (EOC). "
For those who are interested in expanding their reach from University TTOs and those interested in simultaneously doing some good in the world this is a very strong wake up call. Congratulations to the Yale TTO team! (Lita are you still there?) It shows us again that there may be great value to what is done in early research in the right markets. The traditional thinking is simply out the window! It is all the more ironic to me to see this article since the CECR grants were announced only DAYS ago and I came to hear that Peter Singer et al from the University of Toronto, who had proposed to do VERY similar things along these lines for all of Canada, were turned down. No doubt more informed minds than mine have made that decision but to me this was very confusing. Your comments are always welcome.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment